Pretreatment System Inflammation Response Index (SIRI) is a Valuable Marker for Evaluating the Efficacy of Neoadjuvant Therapy in Breast Cancer Patients.

IF 2.1 4区医学 Q2 MEDICINE, GENERAL & INTERNAL International Journal of General Medicine Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI:10.2147/IJGM.S478000

Yunuo Zhang, Jingna Wu, Weiming Chen, Xinhong Liang

{"title":"Pretreatment System Inflammation Response Index (SIRI) is a Valuable Marker for Evaluating the Efficacy of Neoadjuvant Therapy in Breast Cancer Patients.","authors":"Yunuo Zhang, Jingna Wu, Weiming Chen, Xinhong Liang","doi":"10.2147/IJGM.S478000","DOIUrl":null,"url":null,"abstract":"Objective: Immune inflammatory response are involved in the development and progression of cancer. However, there are still inconsistent research results on the value of peripheral blood inflammatory indicators for evaluating the efficacy of neoadjuvant therapy (NAT) in breast cancer. The purpose of this study was to investigate the relationship between pretreatment systemic immune inflammatory response index (SII), systemic inflammatory response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR) and NAT efficacy in breast cancer.Methods: A retrospective analysis was performed on 326 patients with breast cancer who underwent NAT at Meizhou People's Hospital from November 2017 to October 2023. Clinicopathological data was collected, including gender, age, body mass index (BMI), hypertension, diabetes mellitus, family history of cancer, TNM stage, and the molecular subtypes of breast cancer. The optimal cutoff values of SII, SIRI, NLR, PLR, and LMR were calculated using receiver operating characteristic (ROC) curve, and the relationship between inflammatory indexes and other clinicopathological features and the efficacy of NAT was analyzed.Results: In this study, 162 (49.7%) breast cancer patients did not respond to NAT and 164 (50.3%) patients responded to NAT. The levels of SII (p=0.002), SIRI (p<0.001), and NLR (p=0.006) in patients who responded to NAT were significantly higher than those in patients who did not. When the efficacy of NAT was considered as the endpoint of SII, SIRI, and NLR, the critical value of the SII, SIRI, and NLR was 572.53 (under the ROC curve (AUC)=0.598), 0.745 (AUC=0.630), and 2.325 (AUC=0.588), respectively. Logistic regression analysis showed that a high SIRI level (≥0.745/<0.745, OR: 2.447, 95% CI: 1.375-4.357, p=0.002) was an independent factor associated with the efficacy of NAT in breast cancer patients.Conclusion: High SIRI levels (≥0.745) may be an independent factor associated with the efficacy of NAT in patients with breast cancer.","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439349/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S478000","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Immune inflammatory response are involved in the development and progression of cancer. However, there are still inconsistent research results on the value of peripheral blood inflammatory indicators for evaluating the efficacy of neoadjuvant therapy (NAT) in breast cancer. The purpose of this study was to investigate the relationship between pretreatment systemic immune inflammatory response index (SII), systemic inflammatory response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR) and NAT efficacy in breast cancer.

Methods: A retrospective analysis was performed on 326 patients with breast cancer who underwent NAT at Meizhou People's Hospital from November 2017 to October 2023. Clinicopathological data was collected, including gender, age, body mass index (BMI), hypertension, diabetes mellitus, family history of cancer, TNM stage, and the molecular subtypes of breast cancer. The optimal cutoff values of SII, SIRI, NLR, PLR, and LMR were calculated using receiver operating characteristic (ROC) curve, and the relationship between inflammatory indexes and other clinicopathological features and the efficacy of NAT was analyzed.

Results: In this study, 162 (49.7%) breast cancer patients did not respond to NAT and 164 (50.3%) patients responded to NAT. The levels of SII (p=0.002), SIRI (p<0.001), and NLR (p=0.006) in patients who responded to NAT were significantly higher than those in patients who did not. When the efficacy of NAT was considered as the endpoint of SII, SIRI, and NLR, the critical value of the SII, SIRI, and NLR was 572.53 (under the ROC curve (AUC)=0.598), 0.745 (AUC=0.630), and 2.325 (AUC=0.588), respectively. Logistic regression analysis showed that a high SIRI level (≥0.745/<0.745, OR: 2.447, 95% CI: 1.375-4.357, p=0.002) was an independent factor associated with the efficacy of NAT in breast cancer patients.

Conclusion: High SIRI levels (≥0.745) may be an independent factor associated with the efficacy of NAT in patients with breast cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗前系统炎症反应指数（SIRI）是评估乳腺癌患者新辅助疗法疗效的重要标志。

目的：免疫炎症反应与癌症的发生和发展有关。然而，关于外周血炎症指标对乳腺癌新辅助治疗（NAT）疗效的评估价值，研究结果仍不一致。本研究旨在探讨治疗前全身免疫炎症反应指数（SII）、全身炎症反应指数（SIRI）、中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、淋巴细胞与单核细胞比值（LMR）与乳腺癌新辅助治疗疗效之间的关系：对2017年11月至2023年10月在梅州市人民医院接受NAT治疗的326例乳腺癌患者进行回顾性分析。收集临床病理数据，包括性别、年龄、体重指数（BMI）、高血压、糖尿病、癌症家族史、TNM分期和乳腺癌分子亚型。利用接收者操作特征曲线（ROC）计算了SII、SIRI、NLR、PLR和LMR的最佳临界值，并分析了炎症指标和其他临床病理特征与NAT疗效之间的关系：在这项研究中，162 名（49.7%）乳腺癌患者对 NAT 无反应，164 名（50.3%）患者对 NAT 有反应。对 NAT 有反应的患者的 SII 水平（p=0.002）和 SIRI 水平（pp=0.006）明显高于没有反应的患者。当以 SII、SIRI 和 NLR 作为 NAT 疗效的终点时，SII、SIRI 和 NLR 的临界值分别为 572.53（ROC 曲线下（AUC）=0.598）、0.745（AUC=0.630）和 2.325（AUC=0.588）。逻辑回归分析表明，高 SIRI 水平（≥0.745/p=0.002）是与乳腺癌患者 NAT 疗效相关的独立因素：结论：高 SIRI 水平（≥0.745）可能是与乳腺癌患者 NAT 疗效相关的独立因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of General Medicine Medicine-General Medicine

自引率

0.00%

发文量

1113

审稿时长

16 weeks

期刊介绍： The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal. As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.